New hope for new moms: early access to postpartum depression drug
NCT ID NCT03924492
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 26 times
Summary
This program offers early access to ZULRESSO (brexanolone) for a limited number of adult women with postpartum depression before the drug is commercially available. A healthcare provider must request access for a specific patient, and both the patient and provider must agree that the benefits outweigh the risks. The goal is to provide treatment to eligible women who may not have other options.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POSTPARTUM DEPRESSION are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.